U.S. markets close in 3 hours 13 minutes
  • S&P 500

    4,669.75
    +75.13 (+1.64%)
     
  • Dow 30

    35,248.83
    +349.49 (+1.00%)
     
  • Nasdaq

    15,814.09
    +322.43 (+2.08%)
     
  • Russell 2000

    2,259.89
    +13.96 (+0.62%)
     
  • Crude Oil

    71.11
    +2.96 (+4.34%)
     
  • Gold

    1,784.70
    -3.40 (-0.19%)
     
  • Silver

    22.83
    -0.31 (-1.34%)
     
  • EUR/USD

    1.1271
    -0.0048 (-0.43%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • GBP/USD

    1.3298
    -0.0040 (-0.30%)
     
  • USD/JPY

    113.7500
    +0.4400 (+0.39%)
     
  • BTC-USD

    58,692.04
    +4,822.30 (+8.95%)
     
  • CMC Crypto 200

    1,469.12
    +40.19 (+2.81%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,283.92
    -467.70 (-1.63%)
     

Revance Stock Loses 39% Of Its Value After FDA Rejects Its Frown Lines Injection

·2 min read
Revance Stock Loses 39% Of Its Value After FDA Rejects Its Frown Lines Injection
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The FDA rejected Revance Therapeutics' frown lines treatment, depressing RVNC stock which fell to an 18-month low on Monday.